FDA Approval in Just One Month

The U.S. Food and Drug Administration (FDA) approved Rasonque (dolaksonasib) from Revolution Medicines, Inc. (RVMD) on August 26, 2026. The drug is indicated for adult patients with metastatic pancreatic ductal adenocarcinoma who have received at least one prior systemic therapy or are ineligible for multi-agent systemic therapy. Rasonque is a once-daily oral therapy in the approval and commercialization stage. The approval came just one month after the application was submitted on July 22, a result of the combined application of Breakthrough Therapy, Orphan Drug, Priority Review, and the FDA's National Priority Voucher. This approval is considered to have reset the review timeline for serious cancers, as it was expedited by 6.5 months compared to the standard Prescription Drug User Fee Act (PDUFA) timeline.

60% Reduction in Risk of Death in Phase 3

The approval was based on the randomized, open-label, multi-center Phase 3 RASolute 302 trial, which compared Rasonque with standard chemotherapy in 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma. The median overall survival was 13.2 months for Rasonque versus 6.7 months for standard chemotherapy, with Rasonque reducing the risk of death by 60%. The trial was stopped early after achieving all its endpoints in an interim analysis. The clinical benefit was observed not only in the RAS G12 mutation subgroup, which was the focus of patient selection, but also in the overall population, broadening the drug's applicability. Key safety concerns that will determine commercial success include rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite, and bleeding.

Molecular Glue Expanding RAS Targeting

Rasonque is the first approved multi-selective RAS(ON) inhibitor, forming a triple complex by binding active RAS (ON) protein with cyclophilin A (CypA). Compared to Amgen (AMGN)'s Lumakras (sotorasib) and Bristol Myers Squibb (BMY)'s Krazati (adagrasib), which target only KRAS G12C, Rasonque has a broader target range. Neither of these two drugs is approved as a standard treatment for pancreatic cancer. The real competitive axis is Onivyde (liposomal irinotecan, a topoisomerase I inhibitor) in combination with 5-fluorouracil and leucovorin, among other second-line chemotherapies. Given the clear survival benefit, Rasonque has the potential to rapidly change the prescribing structure between genotype-based therapies and conventional cytotoxic agents.

Transition to a Major Commercial Asset

In the U.S., approximately 67,000 cases of pancreatic cancer are diagnosed annually, with 90–95% being pancreatic ductal adenocarcinoma, indicating a large patient population. The 30-day supply list price is USD 39,800, and RBC Capital Markets forecasts peak annual sales of USD 11.5 billion and USD 1.1 billion in 2027. Over 2,000 patients had already received the drug through an expanded access program by early August 2026, securing a favorable starting point for initial demand conversion. The European Medicines Agency (EMA) is currently conducting a stepwise review, and the company is expanding into first-line and adjuvant therapy for pancreatic cancer and a Phase 3 trial for non-small cell lung cancer, aiming to grow the single-approval asset into a multi-tumor-type franchise.